Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Liposarcoma × Troglitazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Pancreatic Neoplasms 1 Liposarcoma 1 Diabetes Mellitus, Type 2 1

Interventions

Radiotherapy 8 Doxorubicin 7 pazopanib 5 palbociclib 4 Trabectedin 4 Gemcitabine 4 ribociclib 3 pembrolizumab 3 eribulin 3 selinexor 2 liposomal doxorubicin 2 avelumab 2 Sunitinib 2 Radiation Dose Hypofractionation 2 Magnetic Resonance Spectroscopy 2 Immunoglobulin G 2 Ifosfamide 2 Docetaxel 2 Cyclophosphamide 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zimberelimab 1 temsirolimus 1 sotigalimab 1 sodium thiosulfate 1 sitravatinib 1 silmitasertib 1 sargramostim 1 romidepsin 1 regorafenib 1 plitidepsin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00003058 2017-02-13

Troglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡